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ABSTRACT
Purpose
This phase III randomized trial (ISRCTN 52253218) compared two chemotherapy regimens,
gemcitabine plus carboplatin and mitomycin, ifosfamide, and cisplatin, in chemotherapy-
naive patients with advanced non–small-cell lung cancer (NSCLC). The regimens were
compared with regard to effects on survival, response rates, toxicity, and quality of life.
Patients and Methods
Eligible patients had previously untreated stage IIIB or IV NSCLC suitable for cisplatin-based
chemotherapy. Randomly assigned patients were to receive four cycles, each at 3-week
intervals, of carboplatin area under the curve of 5 on day 1 plus gemcitabine 1,200 mg/m
2 on
days 1 and 8 (GCa) or mitomycin 6 mg/m
2, ifosfamide 3g/m
2, and cisplatin 50 mg/m
2 on day
1 (MIC).
Results
Between February 1999 and August 2001, 422 patients (GCa, n  212; MIC, n  210) were
randomly assigned in the United Kingdom. The majority of patients received the intended
four cycles (GCa, 64%; MIC, 61%). There was a signiﬁcant survival advantage for GCa
compared with MIC (hazard ratio, 0.76; 95% CI, 0.61 to 0. 93; P  .008). Median survival was
10 months with GCa and 7.6 months with MIC (difference, 2.4 months; 95% CI, 1.0 to 4.0),
and 1-year survival was 40% with GCa and 30% with MIC (difference, 10%; 95% CI, 3% to
18%). Overall response rates were similar (42% for GCa v 41% for MIC; P  .84). More
thrombocytopenia occurred with GCa (P  .03), but this was not associated with increased
hospital admission or fatality. GCa caused less nausea, vomiting, constipation, and alopecia
and was associated with fewer admissions for administration and better quality of life.
Conclusion
In patients with advanced NSCLC, GCa chemotherapy was shown to be a better-tolerated
treatment that conferred a survival advantage over MIC.
J Clin Oncol 23:142-153. © 2005 by American Society of Clinical Oncology
INTRODUCTION
Thecombinationofmitomycin,ifosfamide,
andcisplatin(MIC)iswidelyusedinEurope
for the treatment of non–small-cell lung
cancer (NSCLC), and the combination has
been shown by Cullen et al
1 to improve me-
dian survival by approximately 2 months
compared with supportive care in patients
withadvanceddisease.Inthattrial,theover-
allresponseratetoMICwas31%(complete
response, 2%; partial response, 29%), but
toxicityscoreswerenotreported.
1Inastudy
that compared three cisplatin-containing
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142regimensinpatientswithstageIIIBorIVNSCLC,theresponse
ratereportedwithMICwas40%.
2Inthisstudy,grade3and4
neutropenia occurred in 21% of patients and grade 3 and 4
thrombocytopenia occurred in 10% of patients.
2
New drugs that have activity with low toxicity include
gemcitabine (diﬂuorodeoxycytidine), a deoxycytidine ana-
logthatisapyrimidineantimetabolitewhosemechanismof
action has been well characterized.
3 As a single agent, gem-
citabine has response rates of 20% to 26% in advanced
NSCLC.
4 Preclinical studies suggest synergy between gem-
citabine and cisplatin,
5 and clinical studies have demon-
strated higher response rates and longer survival with the
combination than with gemcitabine alone.
6
Carboplatin is more suitable for outpatient adminis-
tration because prehydration is unnecessary, and it is less
nephrotoxic and neurotoxic. Because of these advantages,
and probable comparable efﬁcacy, carboplatin is an attrac-
tive alternative to cisplatin for combination with gemcitab-
ine. An initial phase I study demonstrated the feasibility of
combiningthedrugs,withdose-limitingmyelosuppression
atapredictedcarboplatinareaunderthecurve(AUC)of5.2
mg/mL/min on a 4-week schedule with gemcitabine 1,000
mg/m
2 on days 1, 8, and 15.
7 Symptomatic toxicity was
similar to single-agent gemcitabine, and grade 4 neutrope-
nia and thrombocytopenia were not associated with any
serious clinical sequelae. However, a subsequent phase II
trial suggested unacceptable toxicity in the form of throm-
bocytopenia using this 4-week schedule.
8 A 3-week sched-
ule of carboplatin AUC 5 on day 1 and gemcitabine 1,250
mg/m
2 on days 1 and 8 is associated with less thrombocy-
topenia than the 4-week schedule and was being used with
acceptabletoxicitybySederholmetal
9oftheSwedishLung
CancerGroup,whohavesubsequentlypresenteddatadem-
onstrating superior survival with this combination com-
pared with gemcitabine alone.
For the current trial, we selected a 3-week schedule of
gemcitabine in combination with carboplatin (GCa) to
comparewithMIC,whichwasthentheLondonLungCan-
cer Group standard regimen, in patients with advanced
(stage IIIB or IV) NSCLC. The trial was a multicenter,
randomized, phase III, open-label study to compare the
regimens with respect to survival, response rate, toxicity,
and quality of life (QOL).
PATIENTS AND METHODS
Eligibility Criteria
Chemotherapy- and radiotherapy-naive patients with a his-
tologic or cytologic diagnosis of stage IIIB or IV NSCLC and who
were18yearsoldwithmeasurableornonmeasurablebutassess-
able disease were eligible. Patients were required to have adequate
bone marrow reserve (WBC count  3,000/L, platelet count
 100,000/L, and hemoglobin 10 g/dL) and renal function
adequate for chemotherapy ( 60 mL/min where measured by
Cr-51-EDTA or  50 mL/min where measured by creatinine
clearance or calculated by Cockroft and Gault formula
10). A his-
tory of prior malignant tumor (unless there was no evidence of
disease for at least 3 years or the tumor was a nonmelanoma skin
tumor), a medical condition that excluded the use of chemother-
apy,symptomaticbrainmetastases,oralifeexpectancyoflessthan
8weeksrenderedpatientsineligiblefortrialentry.Approvalsfrom
the London Multi-Centre Research Ethics Committee and local
research ethics committees were obtained for the trial, and all
patients provided written informed consent.
Treatment Allocation
To randomly assign a patient, center staff completed a ran-
domization checklist and telephoned the London Lung Cancer
Group trials ofﬁce. Patients were randomly allocated to receive
GCaorMICusingamanualminimizationprocedurestratiﬁedby
study center, stage (IIIB or IV), Eastern Cooperative Oncology
Group(ECOG)performancestatus(0,1,2,or3),histology(squa-
mous, adenocarcinoma, or other NSCLC), sex, and age ( 70 or
 70 years). The aim of minimization is to minimize any differ-
ences occurring by chance in the number of patients between the
two treatment groups in the strata speciﬁed by the stratiﬁcation
factors above in each center.
PatientswererandomlyassignedtoreceivefourcyclesofGCa
orMICevery21days.Gemcitabinehasmostfrequentlybeenused
atadoseof1,000mg/m
2ondays1,8,and15ofa4-weekcycle(ie,
an average dose-intensity of 750 mg/m
2/wk). Because we used a
3-weekschedule,agemcitabinedoseof1,200mg/m
2ondays1and
8wasgiventomaintainadose-intensityofgemcitabinecompara-
bletothatofthe4-weekregimen.CarboplatinAUC5wasadmin-
istered on day 1 after the gemcitabine infusion. We used the
Calvert formula
11 to determine the dose of carboplatin (in total
milligrams) as follows: dose in mg  target AUC  (creatinine
clearance  25). The preferred methods for glomerular ﬁltration
rate (GFR) estimation were by Cr-51-EDTA or 24-hour urine
collection;inthesecases,anAUCof5wastobeused(ie,5[GFR
estimated by creatinine clearance  25]). If there were logistic
problems in using either of these methods, GFR could be esti-
mated by calculation (Cockroft and Gault formula
10), and an
AUC of 6 was then recommended because of the approximately
10% underestimation of GFR
12 with this method (ie, 6  [GFR
estimated by Cockroft and Gault  25]). Both gemcitabine and
carboplatin were given intravenously (IV) over 30 minutes.
Patients on the control arm (MIC) received mitomycin 6
mg/m
2 (into a fast-running drip), ifosfamide 3 g/m
2 (in 1 L of
normalsalineover3hours),andcisplatin50g/m
2(in500mLof
normal saline over 1 hour) IV on day 1. Mesna 1.5g/m
2 ( i n1L
of normal saline with 20 mmol of KCl over 4 hours) was also to
be given after the cisplatin.
The protocol required all patients to receive prophylactic
trimethoprim(oralternativeantibioticsaccordingtolocalprefer-
ence in some centers) from day 8 to day 21 of each cycle to
minimize the risk of neutropenic sepsis and respiratory infection.
Suggested antiemetics were granisetron 3 mg IV and dexametha-
sone 8 mg IV before day 1 chemotherapy, metoclopramide 20 mg
IV before day 8 gemcitabine, and metoclopramide 10 mg as re-
quired at other times.
Recommended dose modiﬁcations were based on pretreat-
ment blood tests. For a WBC count of 1,500 to 2,999/Lo ra
platelet count of 50,000 to 99,999/L, all drugs were given at 75%
of the full dose. For a WBC count less than 1,500/L or a platelet
count less than 50,000/L, doses of all drugs were delayed by 1
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2,000/L or the platelet count was less than 50,000/L, the day 8
gemcitabine dose was omitted. For a creatinine clearance of 40 to
60mL/min,cisplatinandgemcitabinewerereducedby50%;ifthe
creatinine clearance was less than 40 mL/min, cisplatin and gem-
citabine doses were omitted.
Use of thoracic or other radiotherapy after completion of
chemotherapy and use of second-line chemotherapy were left to
the discretion of treating clinicians.
Assessments at Baseline, During Treatment, and
During Follow-Up
Patients were assessed at baseline and at each attendance for
chemotherapy, then every 4 weeks for the ﬁrst year and thereafter
at 8-week intervals. Assessments at baseline and during treatment
included history and physical examination (including weight and
height), ECOG performance status, and full blood count. Mini-
mum baseline imaging consisted of chest radiograph and, if the
lesion could not be assessed by this method, computed tomogra-
phy (CT) of the thorax, CT or ultrasound of the abdomen, and, if
clinically indicated, CT brain and isotope bone scan.
Toxicities were assessed according to National Cancer Insti-
tute Common Toxicity Criteria after each cycle (version 2.0, re-
vised1994).Theworstgradesincethelasttreatmentwasrecorded
on trial forms. Patients were evaluated for response at the start of
each cycle by chest radiograph. When disease was measurable or
assessable only by CT of the thorax, the scan was repeated after
every second cycle. Extrapulmonary sites were reassessed by ap-
propriate imaging methods after completion of chemotherapy.
WHO criteria were used to deﬁne response.
13 Disease status and
any additional anticancer treatment were reported at each
follow-up visit.
QOL was assessed using the European Organization for Re-
searchandTreatmentofCancerQualityofLifeQuestionnaireC30
(EORTC QLQ-C30)
14 with lung cancer module LC-17
15 and the
London Lung Cancer Group daily diary card.
16,17 EORTC ques-
tionnaires were completed by the patient at baseline (before
knowledge of the outcome of randomization), 3 weeks after the
start of each cycle, and at the ﬁrst two follow-up visits. Patients
completed the daily diary card at baseline and then every evening
from the ﬁrst day of chemotherapy until 3 weeks after completion
of the last course, scoring each of eight items using a four-point
categoric scale.
Statistical Design and Methods
Power calculations. The primary outcome measure of the
studywasoverallsurvival.OuraimwastodeterminewhetherGCa
couldconferasurvivaladvantagecomparabletothatconferredby
MIC but with less toxicity and better QOL. With an estimated
1-year survival rate of 28% in the MIC group, a total of 387
patients (193 events) would allow us to reliably (80% power, 95%
CI)excludethepossibilitythat1-yearsurvivalwithGCawouldbe
more than 10% worse than with MIC.
For QOL, allowing for 40% noncompliance, 232 patients
conferred approximately 90% power to detect a difference be-
tweenthetreatmentgroupsof20%orgreaterintheproportionof
patients crossing a threshold score on a QOL measure.
Analysis of results. We compared Kaplan-Meier curves for
overall survival and progression-free survival using the standard
log-rank test. The Cox proportional hazards regression model
adjustedbythestratiﬁcationfactors(performancestatus,age,sex,
stage, and cell type) was also applied. Overall survival was deﬁned
as the time from randomization to death from any cause; patients
known to be still alive at the time of the analysis were censored at
the time of their last follow-up. Progression-free survival was
deﬁned as the time from randomization to ﬁrst appearance of
progressive disease or death from any cause; patients known to be
alive and without progressive disease at the time of analysis were
censoredatthetimeoftheirlastfollow-up.Therelativebeneﬁtsin
overall survival and progression-free survival were assessed in an
exploratory manner in subgroups deﬁned by the stratiﬁcation
factors using a 
2 test
18 for interaction (if the factor is a categoric
variable) or a 
2 test for trend (if the factor is an ordinal variable).
The results are presented in Forest plots. For each factor, the
results for each subgroup are displayed. Alongside the subgroup,
the results are the number of deaths and the number of patients
randomlyassignedtoeachofthetreatmentgroups;theestimateof
the hazard ratio (using a center of black square) and CIs are
around the estimate. The size of the square is proportional to the
amount of information in that subgroup, so the larger the square,
the more deaths have occurred in that subgroup. The 
2 test was
used in the response (complete response plus partial response)
rate comparison. The Mann-Whitney test for ordinal data was
applied for the toxicity analysis.
EORTC QOL questionnaires were analyzed using recom-
mended scoring scales and items. Forms with less than 80% of
questions completed and scales with less than 50% of items com-
pleted were excluded. Raw scores for the scales and items of the
questionnaires were compared at speciﬁed time points, and com-
parisonofchangesbetweenbaselineandselectedtimepointswere
made using the Mann-Whitney test for ordinal data. Scores were
also compared by calculation of the area under the score-time
curve over the treatment period. The symptom score recorded by
the diary card over time was plotted to display the changes over
time. The mixed model for repeated measurements using PROC
NLMIXED in SAS (SAS Institute, Cary, NC) was applied in an
exploratory manner for the two treatment comparisons.
19-22 This
was implemented by ﬁtting an ordinal probit model for each
symptom. The treatment allocation and assessment time point
were included in the linear predictor, and a general log likelihood
speciﬁcation was used in the MODEL statement.
All analyses were done on an intention-to-treat basis except
for the analyses of response, toxicity, and daily diary cards, which
were restricted to all patients who received at lease one cycle of
allocated treatment. All P values are two-sided.
RESULTS
Patient Characteristics
Patients were recruited between February 1999 and
August 2001 from 24 centers in the United Kingdom. On
the recommendation of the Independant Data Monitoring
and Ethics Committee, the study recruited beyond the 387
patient target and closed with 422 patients, with 212 pa-
tientsrandomlyassignedtoGCaand210patientsrandomly
assignedtoMIC(Fig1).Thetwoarmswerereasonablywell
balanced with respect to baseline characteristics (Table 1).
Bychance,thereweresmallnonsigniﬁcantexcessesofstage
IVandofperformancestatus0to1patientsintheGCaarm.
On review, ﬁve patients were found not to have met entry
criteria (three patients did not have NSCLC, one patient
Rudd et al
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did not stage IIIB/IV) but were included in the intention-
to-treat survival analyses.
Survival
At the time of analysis, 364 patients (86%) had died,
and 17% of patients randomly assigned to GCa and 11%
randomly assigned to MIC remained alive. The median
follow-up for survivors was 18 months (range, 13 to 40
months). Lung cancer was the predominant cause of death
(90% for GCa; 91% for MIC).
There was a survival beneﬁt in favor of patients who
received GCa (hazard ratio, 0.76; 95% CI, 0.61 to 0.93;
log-rank test P  .008; Fig 2). This translates into an im-
provement of 10% in 1-year survival compared with pa-
tients who received MIC (40% v 30%; 95% CI for
difference, 3% to 18%), and 6% in 2-year survival (12% v
6%; 95% CI for difference, 1% to 12%). For median sur-
vival, the hazard ratio translates into a difference of 2.4
months (10 v 7.6 months; 95% CI for difference, 1.0 to
4.0 months). Because of the small imbalance in baseline
characteristics of performance status and stage, the log-
rank test was also recalculated stratiﬁed by the variables
used in minimization (performance status, age, sex,
stage, and cell type). The result was unaffected (adjusted
Cox model P  .004). Exclusion of the ﬁve patients
subsequentlyfoundtohavenotmetentrycriteriadidnot
affect the conclusions.
Forest plots showing exploratory subgroup analyses
(Fig 3) indicate that the survival advantage of GCa over
MIC applied regardless of age, sex, performance status,
stage, and cell type.
There was no signiﬁcant difference in progression-free
survival (hazard ratio, 0.9; 95% CI, 0.74 to 1.09; log-rank
P  .28; Fig 4). Median progression-free survival was 5.3
monthswithGCaand4.8monthswithMIC(difference,0.5
months; 95% CI, 0.5 to 1.4 months).
Fig 1. Trial proﬁle.
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Best overall response rates (complete and partial re-
sponse) to chemotherapy were very similar (P  .84) be-
tween the two regimens (Table 2). Response rates for the
206patientsoneacharmwhoreceivedatleastonecourseof
chemotherapy were 42% (95% CI, 35% to 49%) with GCa
and 41% (95% CI, 35% to 48%) with MIC.
Treatment
A majority of patients received four cycles of chemo-
therapy (64% for GCa and 61% for MIC). The reasons for
stopping chemotherapy before four cycles were similar in
the two arms, mainly progressive disease (GCa, 48%; MIC,
50%) and toxicity (GCa, 25%; MIC, 24%).
Delays and modiﬁcations were usually due to hemato-
logictoxicity.Theproportionofallcyclesthatweredelayed
(for 7 days or more) was 16% with GCa and 9% with MIC.
The proportion of cycles modiﬁed was 16% with GCa and
9% with MIC. These differences occurred mainly because
the day 8 chemotherapy on the GCa schedule doubled the
opportunities for modiﬁcation.
Toxicity
Two hundred six patients in each arm received at least
one cycle of allocated chemotherapy. There was slightly
more thrombocytopenia with GCa using a test for trend
over the whole range of grades (P  .03). This excess was
largely due to increased occurrence of grade 2 thrombocy-
topenia,withnosigniﬁcantdifferenceinfrequencyofgrade
3 and 4 thrombocytopenia; thrombocytopenia was seldom
symptomatic. There were no differences in anemia, leuko-
penia, and neutropenia (Table 3).
Nausea,vomiting,alopecia,andconstipationweresig-
niﬁcantly worse with MIC. Rash and allergic reactions oc-
curredmorecommonlywithGCa,butnearlyallweremild.
There were no differences between the arms for infection,
stomatitis, diarrhea, or anorexia (Table 4). No differences
between the arms were seen for other toxicity items re-
quested on data forms, including fever, myalgia, rigors,
hematuria, and desquamation, which were all mild and
occurred in less than 15% of patients (not listed). Four
deaths (2%) on each arm were attributed wholly or in part
to chemotherapy.
Hospital Admissions
Patientswereadmittedtothehospitalovernightforthe
administration of 14% of GCa cycles and 90% of MIC
cycles. Of the admissions related to GCa administration,
78%werefortheﬁrstcycle.Ofthepatientsreceivingtwo
or more cycles of GCa, 30% were admitted at least once
betweencycles,comparedwith26%ofpatientsreceiving
MIC. These admissions were predominantly related to
toxicity (61% of admissions for GCa; 52% of admissions
for MIC).
Additional Anticancer Therapy
Thoracic radiotherapy was given after chemotherapy
to 41 (19%) of 212 patients who received GCa and to 34
(16%)of210patientswhoreceivedMIC(P.40).Dosesof
radiotherapy received varied greatly, with similar ranges in
both arms (10 to 64 Gy for GCa; 10 to 66 Gy for MIC). Of
Table 1. Patient Characteristics
GCa
(n  212)
MIC
(n  210)
No. of
Patients %
No. of
Patients %
Age, years
Median 62 63
Range 40-81 34-81
Sex
Male 147 69 149 71
Female 65 31 61 29
ECOG performance status
0 6 43 0 4 42 1
1 124 58 133 63
2 19 9 29 14
35 2 4 2
Stage
IIIB 95 45 105 50
IV 117 55 105 50
Cell type
Squamous 85 40 89 42
Adenocarcinoma 79 37 70 33
Other NSCLC 48 23 51 24
NOTE. The P values for patient characteristics were .65, .72, .07, .29,
and .70 for age, sex, performance status (0 to 1 v 2 to 3), stage, and cell
type, respectively, using 
2 test for frequency except for age, for which
a t test was used.
Abbreviations: GCa, gemcitabine and carboplatin; MIC, mitomycin,
ifosfamide, and cisplatin; ECOG, Eastern Cooperative Oncology Group;
NSCLC, non–small-cell lung cancer.
Fig 2. Overall survival. Hazard ratio  0.76; 95% CI, 0.61 to 0.93;
log-rank P  .008. MIC, mitomycin, ifosfamide, and cisplatin; GCa,
gemcitabine and carboplatin.
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MICpatientscomparedwithfour(10%)of41GCapatients
received doses of 50 Gy or more (P  .03). Second-line
chemotherapy was given to 18 (8%) of 212 GCa patients
and to 12 (6%) of 210 MIC patients (P  .27). Docetaxel
was the most commonly used agent.
QOL
Compliance with the QOL questionnaires was similar
between the arms and decreased over time. Baseline ques-
tionnaireswerecompletedby91%ofpatientsonbotharms;
by 6 weeks, this had decreased to 79% on GCa and 83% on
MIC, and by 12 weeks, this had decreased to 53% on GCa
and 57% on MIC. All scales/items measured by EORTC
QLQ-C30 and LC-17 questionnaires were well balanced
acrossthetwotreatmentgroupsatthepretreatmentassess-
ment.Themostcommonsymptomspresent“quiteabit”or
“very much” at baseline were cough in 45% of patients,
fatigue in 42%, and dyspnea in 40%.
Fig 3. Subgroup analysis on overall sur-
vival. (Pt test for trend, Pi test for inter-
action.) *Intermediate dashes within
error bars  95% CI. MIC, mitomycin,
ifosfamide, and cisplatin; GCa, gemcitab-
ine and carboplatin.
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6 weeks showed signiﬁcant advantages for GCa over MIC
with respect to nausea and vomiting, appetite loss, consti-
pation, fatigue, hair loss and being upset by hair loss,
physical functioning, and role functioning (Table 5). Com-
parison of changes in scores between baseline and 12 weeks
showedpersistentsigniﬁcantadvantagesforGCaoverMIC
with respect to hair loss, nausea, and vomiting. AUC anal-
yses over 12 weeks showed signiﬁcant advantages for GCa
with respect to hair loss, nausea, and vomiting (Table 5).
Diary cards were completed for 12 weeks. Compliance
was high initially, with 78% of patients on GCa and 73% on
MIC completing cards during the ﬁrst 3 weeks, but decreased
over time. Plots of percentage of patients scoring greater than
one for each of the eight questions are shown in Figure 5. All
items except pain showed a trend in favor of GCa over MIC,
but only nausea and vomiting reached statistical signiﬁcance.
DISCUSSION
This trial demonstrates that GCa confers longer survival
and is better tolerated than MIC in patients with advanced
NSCLC.Theconsistencyofthetreatmenteffectacrossstage
and performance subgroups strengthens conﬁdence in the
validity of the results. The median and 1-year survival (7.6
months, 30%) for MIC was slightly better than previous
results for this exact regimen in a United Kingdom trial
comparing chemotherapy with no chemotherapy in pa-
tients with advanced disease (6.7 months and 25%),
1 so
there is no reason to believe that spuriously poor results
with MIC in the present study could explain the difference.
The cisplatin dose used within the MIC regimen, although
Fig 4. Progression-free survival. Hazard ratio  0.9; 95% CI, 0.74 to 1.09;
log-rank P  .28. MIC, mitomycin, ifosfamide, and cisplatin; GCa, gemcit-
abine and carboplatin.
Table 2. Best Overall Response to Treatment
GCa
(n  206)
MIC
(n  206)
No. of
Patients %
No. of
Patients %
C R 3194
PR 84 41 76 37
SD 76 37 75 36
PD 28 14 32 15
NA 15 7 14 7
Overall response rate,%
CR  PR 42 41
95% CI 35 to 49 35 to 48
NOTE. Patients were deemed not assessable for response if their
response could not be determined because they died before reassess-
ment (MIC, n  12; GCa, n  12), were not reassessed (MIC, n  2; GCa,
n  2), or had received intended chemotherapy but were later found to
have been inappropriately entered (GCa, n  1).
Abbreviations: GCa, gemcitabine and carboplatin; MIC, mitomycin,
ifosfamide, and cisplatin; CR, complete response; PR, partial response;
SD, stable disease; PD, progressive disease; NA, not assessable.
Table 3. Hematologic Toxicity for Patients Who Received at Least
One Cycle of Allocated Treatment
Reported Worst
Toxicity
% of Patients
P
(Mann-Whitney)
GCa
(n  200/202)

MIC
(n  201/202)

Anemia, grade
0 2 4 .14
12 6 3 2
26 1 5 4
37 8
42 1
Leucopenia, grade
0 27 24 .30
12 3 2 6
22 8 2 2
31 9 2 2
43 6
Neutropenia, grade
0 28 34 .49
11 3 1 2
22 4 2 1
32 1 1 8
41 3 1 5
Thrombocytopenia, grade
0 45 48 .03
12 8 3 8
23 6
31 1 4
41 3 3
Abbreviations: GCa, gemcitabine and carboplatin; MIC, mitomycin,
ifosfamide, and cisplatin.
A total of 206 patients in each arm received at least one course. Data
were unavailable for four patients on GCa for anemia, leukopenia, and
thrombocytopenia and for six patients for neutropenia and for four
patients on MIC for anemia, leukopenia, and neutropenia and ﬁve
patients for thrombocytopenia.
Rudd et al
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Europe, is standard within the United Kingdom. The
medianand1-yearsurvivalforGCa(10months,40%)were
comparable to those reported with a similar GCa regimen
(11 months, 44%) when compared with gemcitabine
alone.
9Our1-yearsurvivalwithGCawasalsosimilartothat
reportedwithgemcitabineandcisplatin(36%)inanECOG
trial, which found no signiﬁcant survival differences be-
tween that regimen, cisplatin/paclitaxel (31%), cisplatin/
docetaxel (31%), and carboplatin/paclitaxel (34%).
23 Our
studyhadahigherproportionofstageIIIBpatientsbutalso
a higher proportion of performance status 2 or 3 patients
than the ECOG study.
A smaller trial (307 patients) comparing a 4-week reg-
imen of gemcitabine 1,000 mg/m
2 on days 1, 8, and 15 plus
cisplatin 100 mg/m
2 day 2 with MIC using a higher dose of
cisplatin (100 mg/m
2) than we used (50 mg/m
2) and giving
sixcyclesratherthanfourresultedinnosigniﬁcantsurvival
difference in median and 1-year survival between MIC (9.6
months, 34%) and gemcitabine with cisplatin (8.6 months,
33%).
24 It is possible that the higher dose of cisplatin may
have conferred some survival advantage, although there is
norandomizedtrialevidencethatdemonstratesthatadose
ofcisplatingreaterthan50mg/m
2confersasurvivaladvan-
tage in this regimen, and the higher dose did confer more
frequent grade 3 or 4 hematologic toxicity than observed
with MIC in our study.
24 A randomized comparison of a
4-week regimen of gemcitabine 1,000 mg/m
2 on days 1, 8,
and15pluscarboplatinAUC5onday1witheitherMICor
mitomycin, vinblastine, and cisplatin (MVP) found no sig-
niﬁcant survival difference, although QOL tended to favor
GCa.
25 It is possible that the survival advantage demon-
strated for GCa in our study may relate to the use of a
3-week rather than 4-week schedule. The 3-week schedule
confers a higher dose-intensity for carboplatin and leads
lessfrequentlytograde3to4thrombocytopeniaandhence
fewer gemcitabine omissions. It seems unlikely that the use
of carboplatin rather than cisplatin with gemcitabine was
responsible for the survival advantage over MIC. A large
randomizedphaseIIIcomparisonofpaclitaxelincombina-
tion with either carboplatin AUC 6 or cisplatin 80 mg/m
2
found a 1.6-month median survival advantage for cisplatin
in an extended follow-up but with more nausea, vomiting,
andnephrotoxicity.
26AsmallerrandomizedphaseIIIcom-
parison of a 3-week schedule of gemcitabine in combina-
tion with either carboplatin AUC 5 or cisplatin 80 mg/m
2
showed no signiﬁcant survival difference but more nausea
and vomiting with cisplatin.
27 A recent meta-analysis dem-
onstrated that in combination with a platinum agent, gem-
citabineconfersasurvivaladvantageoverotheragents,and
this may be relevant.
28
In our study, progression-free survival was not signiﬁ-
cantly better for GCa. The protocol required follow-up visits
monthlyfortheﬁrstyearandevery2monthsthereafter,butin
Table 4. Nonhematologic Toxicities for Patients Who Received at Least
One Cycle of Allocated Treatment
Reported Worst Toxicity
% of Patients
P
(Mann-Whitney)
GCa
(n  197)
 MIC
(n  201/202)

Allergy, grade
0 93 97 .049
15 2
21 1
31 0
40 0
Nausea, grade
0 36 23 .0001
13 7 3 5
22 2 2 9
35 1 2
40 1
Vomiting, grade
06 4 4 5  .0001
12 0 2 6
21 2 1 9
33 8
41 2
Alopecia, grade
05 8 1 7  .0001
13 6 2 6
26 4 8
31 9
Rash, grade
07 9 9 4  .0001
11 4 3
27 2
31 0
40 0
Constipation, grade
0 52 39 .005
13 0 3 6
21 6 1 7
32 7
40 0
Infection, grade
0 70 72 .54
16 8
21 6 1 2
37 6
41 1
Stomatitis, grade
0 71 66 .52
11 8 2 7
21 0 5
31 2
40 0
Diarrhea, grade
0 82 83 .67
11 2 1 2
24 3
32 2
41 1
Anorexia, grade
0 51 51 .50
13 2 2 3
21 2 1 9
35 6
41 1
Abbreviations: GCa, gemcitabine and carboplatin; MIC, mitomycin,
ifosfamide, and cisplatin.
A total of 206 patients in each arm received at least one course. Data
were unavailable for nine patients on GCa and four patients on MIC for
nausea, vomiting, alopecia, infection, stomatitis, and diarrhea and ﬁve
patients for allergy, rash, constipation, and anorexia.
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tainment of date of progression prone to inaccuracy.
This may have resulted in underestimation of the differ-
ence between the arms. A few more patients in the GCa
arm received additional treatment in the form of radio-
therapy or second-line chemotherapy, but this was offset
byasigniﬁcantlygreaterproportionofpatientsreceiving
what could be deemed a radical dose (at least 50 Gy) of
thoracic radiotherapy in the MIC arm. Low-dose pallia-
tive radiotherapy does not prolong survival, and the
survival advantage conferred by second-line chemother-
apyissmallatbest,soitisimplausiblethattheseminordiffer-
ences could account for the survival advantage for GCa.
GCa was associated with more thrombocytopenia, but
there was no signiﬁcant difference between the arms in
frequencyofhospitaladmissionbetweenchemotherapycy-
cles. Recorded full blood counts obtained pretreatment on
day 1, on day 8 for GCa, and where available at nadir were
graded for toxicity. Nadir counts were not usually per-
formed for patients receiving MIC, so that hematologic
toxicity may have been under-reported in this arm. Symp-
tomatic toxicities such as nausea and vomiting were less
Table 5. Quality-of-Life Data (EORTC questionnaires)
Scale
Baseline
(%)
6 Weeks
P Value
of MW
Test
12 Weeks
P Value
of MW
Test
Score at Week 6 Minus Baseline Score at Week 12 Minus Baseline
GCa MIC GCa MIC
GCa MIC Median IQR Median IQR Median IQR Median IQR
EORTC QLQ-C30
Functional scales
Physical 33 33 0 0.20-0.20 0 0.20-0.40 .014 0 0.20-0.40 0.20 0.20-0.55 .35
Role 40 44 0 0.50-0.50 0 0.50-1.0 .009 0 0.50-0.50 0 0-1.0 .27
Emotional 31 33 0.25 0.75-0.25 0.25 0.50-0.25 .45 0.25 0.75-0.25 0.25 0.50-0 .97
Cognitive 14 12 0 0.50-0 0 0.50-0.50 .62 0 0.50-0 0 0.50-0.50 .56
Social 28 32 0 0.50-0.50 0 0.50-1.0 .15 0 0-0.50 0 0.50-1.0 .83
Global health status, QOL 28 23 0 0.75-1.0 0 1.0-0.50 .018 0 1.0-1.0 0 1.0-0.50 .12
Symptom scales/items
Fatigue 41 44 0 0.33-0.33 0 0.33-0.67 .10 0 0.33-0.67 0.33 0.33-0.67 .19
Nausea and vomiting 7 6 0 0-0 0 0-0.50 .006 0 0-0 0 0-0.50 .04
Pain 27 24 0 0.50-0 0 0.50-0 .58 0 0.50-0 0 0.50-0 .72
Dyspnea 38 40 0 1.0-0 0 1.0-0 .71 0 1.0-0 0 0-0 .58
Insomnia 28 32 0 1.0-1.0 0 1.0-0 .30 0 1.0-1.0 0 1.0-0 .32
Appetite loss 28 27 0 1.0-0 0 0-1.0 .03 0 1.0-0 0 1.0-0 .75
Constipation 19 12 0 0-0 0 0-1.0 .02 0 0-0 0 0-0 .25
Diarrhea 3 1 0 0-0 0 0-0 .08 0 0-0 0 0-0 .13
Financial difﬁculties 17 19 0 0-0 0 0-0 .86 0 0-0 0 0-0 .06
Average No. of patients 189 190 147 147 90 90
QLQ-LC17
Symptom scales/items
Coughing 46 44 0.5 1.0-0 0.50 1.0-0 .94 0.5 1.0-0 0 0.5-0 .14
Hemoptysis 3 7 0 0-0 0 0-0 .83 0 0-0 0 0-0 .28
Dyspnea 35 36 0 0.42-0.25 0 0.25-0.25 .92 0 0.50-0.25 0 0.25-0.25 .43
Sore mouth 5 3 0 0-0 0 0-0 .68 0 0-0 0 0-0 .42
Dysphagia 7 9 0 0-0 0 0-0 .26 0 0-0 0 0-0 .15
Hoarseness 18 17 0 0-0 0 0-0 .72 0 0-0 0 0-0 .75
Peripheral neuropathy 8 9 0 0-0.33 0 0-0.33 .85 0 0-0.33 0 0.17-0.33 .75
Pain in chest 15 13 0 1.0-0 0 1.0-0 .86 0 1.0-0 0 0.50-0 .99
Hair loss 0 1 0 0-1.0 2.0 1.0-3.0  .0001 0 0-1.0 1.5 1.0-3.0  .0001
Upset by hair loss 3 4 0 0-0 0 0-1.0 .0002 0 0-0 0 0-1 .11
Fever 3 3 0 0-0 0 0-0 .44 0 0-0 0 0-0 .99
Average No. of patients,
excluding hair loss
192 191 146 146 90 88
Average No. of patients, hair loss 131 127 85 94 46 53
NOTE. Scoring: all questions, 1  not at all, 2  a little, 3  quite a bit, 4  very much, except global QOL question: 1  very poor, 7  excellent. Baseline:
percentage of patients with quite a bit/very much for each of scales except for the global health status QOL which is a percentage of patients with rather
poor/poor/very poor. Six weeks: median and IQR of the score at 6 weeks minus score at baseline. Twelve weeks: median and IQR of the score at 12 weeks
minus score at baseline. Negative values mean improvement and positive values mean worse than baseline for each of scale except for the global health
status QOL, which is the other way around.
Abbreviations: EORTC, European Organization for Research and Treatment of Cancer; GCa, gemcitabine and carboplatin; MIC, mitomycin, ifosfamide, and
cisplatin; MW, Mann-Whitney; IQR, interquartile range; QLQ-C30, Quality of Life Questionnaire C30; QOL, quality of life.
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with GCa. GCa was associated with overall better QOL as
assessed by interval questionnaires and daily diary cards.
Clinicians considered it desirable to admit patients over-
night for administration of MIC far more frequently than
GCa because of the hydration requirement for cisplatin
administration. Most of the admissions for GCa were for
theﬁrstcycle,atwhichtimepatientsmayalreadyhavebeen
in hospital after completion of investigations. There may
also have been caution regarding administration of the ﬁrst
course of a relatively new regimen.
Thereisincreasingevidencethatdoubletsusingaplat-
inum agent and one of the newer chemotherapeutic agents
active in lung cancer achieve better results than older trip-
lets. A Portuguese study compared the combination of
MVP (like MIC, a widely used regimen in the United King-
domandEurope)withcisplatinincombinationwitheither
gemcitabine or vinorelbine and found that both the latter
regimens conferred longer survival than MVP.
29 The
United Kingdom National Institute for Clinical Excellence
guidanceforchemotherapyinNSCLC(June2001)statedthat
objectiveassessmentofnewagentswashinderedbythelackof
good studies directly comparing the new agents in combina-
tionwithplatinum-basedtherapywithcombinationregimens
commonlyusedintheUnitedKingdom(ie,MICandMVP).
30
Results from randomized studies are now available and favor
the new agents over both these older regimens.
In patients with advanced NSCLC with limited life
expectancy, the goals of chemotherapy are palliation of
symptoms and modest prolongation of survival. In this
setting, reducing hospital admissions and symptomatic toxic-
ity are important aims. GCa is an effective and well-tolerated
treatmentthattheLondonLungCancerGroupnowregardsas
its standard ﬁrst-line regimen for stage IIIB or IV NSCLC and
therefore as its reference regimen for future studies.
■■■
Appendix
Clinicians and researchers include the following (centers
listed in order of contribution): St Bartholomew’s Hospital,
London(R.M.Rudd,J.P.C.Steele,J.Shamash,P.Wells,and
M. Evans); Clatterbridge Centre for Oncology, Clatter-
bridge (J. Littler, E. Marshall, P.I. Clark, I. Syndikus, J.
Maguire, K. Hyatt, B. Haylock, S.M. O’Reilly, J. Reilly, and
C. Ball); Weston Park Hospital, Shefﬁeld (M. Hatton, P.C.
Lorigan, P.M. Fisher, P. Joyce, R. Bell, Y. Charles, and J.
Bliss); Southampton University Hospitals, Southampton
(P.W.M. Johnson, C. Ottensmeier, T. Goldie, and C.
Gradidge); Norfolk and Norwich and James Paget Hospi-
tals(W.M.C.Martin,J.Oldman,J.Beety,N.Stevens,andK.
Holland); Ninewells Hospital and Medical School (E.M.
Rankin,M.Highley,andD.Forbes);WhittingtonHospital,
London (S.M. Lee, A. Leary, J. Ireland); North Middlesex
Hospital(T.Eisen,H.Bridle,andK.O’Farrell);GuysandSt
Thomas National Health Service Trust (P.G. Harper, P.
Ellis, J. Prendiville, T. Plunkett, A. Poole, and K. Saggers);
Oldchurch Hospital (J. Shamash and L. Huckins); South-
endHospital(A.Lamont,C.Trask,andG.Ogden);Univer-
sity College Hospitals Trust, London (S.M. Lee, S.G. Spiro,
and A. Leary); Sunderland Royal Hospital (I. Taylor,
H.W. Clague, K.K. Sridharan, and J. Anderson); Stobhill
Hospital, Glasgow (R. Milroy, J. McPhelim, and J.
Graham); Edinburgh Cancer Centre (A. Price, J. Ironside,
F.A. Little, F. Dawson, F. Peet, and D. Boyle); North Devon
District Hospital (M. Napier, R. Ayres, and B. Holbrook);
Cheltenham General Hospital (D. Farrugia, P. Jenkins, and
J. Kellaway); St George’s Hospital, London (J.L. Mansi and
J. Clarke); Ysbyty Gwynedd, Bangor (N. Stuart and J.
Jones); Royal Devon and Exeter Hospital (P. Bliss, M.
Napier, C. Ridler, and D. Astill); Darlington Hospital (E.N.
Evans and S.M. Alcock); Torbay Hospital (A. Goodman
andF.Roberts);RoyalBerkshireHospital(P.RogersandC.
Lewis); and Mount Vernon Hospital (P. Ostler).
Trial center staff include the following: Nicole Gower, Paul
Smith, Lindsay James, Susan Wan, and Katy O’Donnell.
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